Breaking News Instant updates and real-time market news.

URGN

UroGen Pharma

$42.46

-0.8 (-1.85%)

19:12
01/18/18
01/18
19:12
01/18/18
19:12

UroGen Pharma 1.463M share Secondary priced at $41.00

The deal size was increased to 1.46M shares from 1.14M shares. Jefferies and Cowen acted as joint book running managers for the offering.

  • 19

    Jan

URGN UroGen Pharma
$42.46

-0.8 (-1.85%)

05/30/17
JEFF
05/30/17
INITIATION
Target $27
JEFF
Buy
UroGen Pharma initiated with a Buy at Jefferies
Jefferies analyst Matthew Andrews started UroGen Pharma with a Buy rating and $27 price target. The analyst believes a growing appreciation for the company's "broad" urothelial cancer portfolio strategy can drive upside in the shares.
11/15/17
RAJA
11/15/17
DOWNGRADE
RAJA
Market Perform
UroGen Pharma downgraded to Market Perform from Outperform at Raymond James
11/15/17
OPCO
11/15/17
NO CHANGE
Target $51
OPCO
Outperform
UroGen Pharma price target raised to $51 from $32 at Oppenheimer
Oppenheimer analyst Derek Archila raised his price target for UroGen Pharma to $51 from $32 after the company reported a Q3 financial and business update. The analyst remains positive on the shares ahead of UroGen's top line data from its OLYMPUS study evaluating MitoGel in patients with low grade upper tract urothelial carcinoma and views MitoGel as a potential game-changer in the way this indication is treated. Archila reiterates an Outperform rating on the shares.
11/15/17
RAJA
11/15/17
DOWNGRADE
RAJA
Market Perform
UroGen Pharma downgraded to Market Perform from Outperform at Raymond James
As previously reported, Raymond James downgraded UroGen Pharma to Market Perform from Outperform. Analyst Reni Benjamin said shares have surpassed his bull case target of $33 and valuation reflects the commercial prospects and risks of the pipeline products including MitoGel and VesiGel.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.